Larimar Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
Mailing Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
Phone
844-511-9056
Fiscal Year End
1231
EIN
203857670
Financial Overview
FY2025
-$80.60M
Net Income
$200.22M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 26, 2026 | View on SEC |
Insider Trading
STRONG BUY
4 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.